List of Contents

Pharmacogenomics Market Size, Share, and Trends 2024 to 2033

Pharmacogenomics Market (By Technology: DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry; By Applications: Drug Discovery, Pain management, Neurology, Oncology, Drug Discovery, Cardiovascular diseases, Infectious diseases, Psychiatry; By End User: Hospitals, Clinics, Research institute, Medical, academic institute; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : June 2024
  • Report Code : 2073
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pharmacogenomics Market 

5.1. COVID-19 Landscape: Pharmacogenomics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pharmacogenomics Market, By Technology

8.1. Pharmacogenomics Market, by Technology, 2024-2033

8.1.1. DNA Sequencing

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Microarray

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Polymerase Chain Reaction

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Electrophoresis

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Mass Spectrometry

8.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Pharmacogenomics Market, By Applications

9.1. Pharmacogenomics Market, by Applications e, 2024-2033

9.1.1. Drug Discovery

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Pain management

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Neurology

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Oncology

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Cardiovascular diseases

9.1.5.1. Market Revenue and Forecast (2021-2033)

9.1.6. Infectious diseases

9.1.6.1. Market Revenue and Forecast (2021-2033)

9.1.7. Psychiatry

9.1.7.1. Market Revenue and Forecast (2021-2033)

9.1.8. Others

9.1.8.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Pharmacogenomics Market, By End User 

10.1. Pharmacogenomics Market, by End User, 2024-2033

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Clinics

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Research institute

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Medical, academic institute

10.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Pharmacogenomics Market, By Distribution Channel 

11.1. Pharmacogenomics Market, by Distribution Channel, 2024-2033

11.1.1. Hospital Pharmacy

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Online Pharmacy

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Retail Pharmacy

11.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Pharmacogenomics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Technology (2021-2033)

12.1.2. Market Revenue and Forecast, by Applications (2021-2033)

12.1.3. Market Revenue and Forecast, by End User (2021-2033)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Technology (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Applications (2021-2033)

12.1.5.3. Market Revenue and Forecast, by End User (2021-2033)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Technology (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Applications (2021-2033)

12.1.6.3. Market Revenue and Forecast, by End User (2021-2033)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Technology (2021-2033)

12.2.2. Market Revenue and Forecast, by Applications (2021-2033)

12.2.3. Market Revenue and Forecast, by End User (2021-2033)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Technology (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Applications (2021-2033)

12.2.5.3. Market Revenue and Forecast, by End User (2021-2033)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Technology (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Applications (2021-2033)

12.2.6.3. Market Revenue and Forecast, by End User (2021-2033)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Technology (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Applications (2021-2033)

12.2.7.3. Market Revenue and Forecast, by End User (2021-2033)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Technology (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Applications (2021-2033)

12.2.8.3. Market Revenue and Forecast, by End User (2021-2033)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Technology (2021-2033)

12.3.2. Market Revenue and Forecast, by Applications (2021-2033)

12.3.3. Market Revenue and Forecast, by End User (2021-2033)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Technology (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Applications (2021-2033)

12.3.5.3. Market Revenue and Forecast, by End User (2021-2033)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Technology (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Applications (2021-2033)

12.3.6.3. Market Revenue and Forecast, by End User (2021-2033)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Technology (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Applications (2021-2033)

12.3.7.3. Market Revenue and Forecast, by End User (2021-2033)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Technology (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Applications (2021-2033)

12.3.8.3. Market Revenue and Forecast, by End User (2021-2033)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Technology (2021-2033)

12.4.2. Market Revenue and Forecast, by Applications (2021-2033)

12.4.3. Market Revenue and Forecast, by End User (2021-2033)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Technology (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Applications (2021-2033)

12.4.5.3. Market Revenue and Forecast, by End User (2021-2033)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Technology (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Applications (2021-2033)

12.4.6.3. Market Revenue and Forecast, by End User (2021-2033)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Technology (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Applications (2021-2033)

12.4.7.3. Market Revenue and Forecast, by End User (2021-2033)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Technology (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Applications (2021-2033)

12.4.8.3. Market Revenue and Forecast, by End User (2021-2033)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Technology (2021-2033)

12.5.2. Market Revenue and Forecast, by Applications (2021-2033)

12.5.3. Market Revenue and Forecast, by End User (2021-2033)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Technology (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Applications (2021-2033)

12.5.5.3. Market Revenue and Forecast, by End User (2021-2033)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Technology (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Applications (2021-2033)

12.5.6.3. Market Revenue and Forecast, by End User (2021-2033)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

Chapter 13. Company Profiles

13.1. Abbott (US)

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Bayer AG (Germany)

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Allergan (Ireland)

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. AbbVie Inc (US)

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GmBH (Germany)

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Teva Pharmaceutical Industries ltd (India)

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Natco Pharma Limited (India)

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Lupin (India)

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Sun Pharmaceutical Industries ltd (India)

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Merck & Co Inc (Germany)

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global pharmacogenomics market size was accounted at USD 16.40 billion in 2023 and it is expected to reach around USD 39.89 billion by 2033.

The global pharmacogenomics market is poised to grow at a CAGR of 9.3% from 2024 to 2033.

The major players operating in the pharmacogenomics market are Abbott (US), Bayer AG (Germany), Allergan (Ireland), AbbVie Inc (US), GmBH (Germany), Teva Pharmaceutical Industries ltd (India), Natco Pharma Limited (India), Lupin (India), Sun Pharmaceutical Industries ltd (India), Merck & Co Inc (Germany), Eli Lilly and Company (US), Squiib Company (US), Novartis AG (Switzerland), Mylan N.V. (US), Ferndale Pharma Group Inc, (US), f. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (US) and Others.

Increased population with increased number of chronic disorders such as cancer, HIV, AIDS, tuberculosis have increased the demand for new drug development drives the pharmacogenomics market to grow high.

North America region will lead the global pharmacogenomics market during the forecast period 2024 to 2033.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us